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Introduction
The TNFSF4 gene, which encodes OX40L, is considered
as a potential autoimmunity candidate gene. OX40L is
expressed on activated antigen presenting cells (APCs)
and endothelial cells in acute inflammation [1]. Further-
more, it enhances B-cell proliferation and differentiation,
and its binding to OX40 (CD134) promotes proliferation
and survival of T-cells and predisposes them to a more
permissive proliferative and survival condition [2]. Inter-
estingly, four TNFSF4 promoter single-nucleotide poly-
morphisms (SNP) were recently implicated in
susceptibility to systemic sclerosis (SSc) [3].
Aim
The aim of this study was to confirm the influence of
TNFSF4 polymorphisms on SSc susceptibility and clini-
cal subtypes or phenotypic features.
Patients and methods
Eight European populations of Caucasian ancestry were
included, comprising a total of 3014 SSc patients and 3125
healthy controls. Four genetic variants of the TNFSF4
gene (rs1234314, rs844644, rs844648 and rs12039904)
were selected as genetic markers and genotyped using
Taqman Allelic Discrimination Assays.
Results
A pooled-analysis revealed the association of rs1234314
and rs12039904 SNPs with SSc [OR=1.15,95%CI 1.02-
1.31;OR=1.18,95%CI 1.08-1.29, respectively].
After subtype stratification, significant association of
the four tested SNPs with the limited cutaneous SSc
(lcSSc) subgroup of patients was revealed [rs1234314
OR=1.22,95%CI 1.07-1.38; rs844644 OR=0.91,95%CI
0.83-0.99; rs844648 OR=1.10,95%CI 1.01-1.20; and
rs12039904 OR=1.20,95%CI 1.09-1.33]. Considering
autoantibody status, the association of three of these
variants, rs1234314, rs844648 and rs12039904 with
anticentromere autoantibody (ACA) positive subset of
patients remained significant [OR=1.23,95%CI 1.10-1.37;
OR=1.12,95%CI 1.01-1.25; OR=1.22,95%CI 1.07-1.38,
respectively]. Haplotype analysis confirmed the existence
of a previously described protective haplotype and
revealed a new risk haplotype with evidence of associa-
tion with SSc [OR=0.88,95%CI 0.82-0.96;OR=1.14,95%CI
1.03-1.26, respectively], lcSSc [OR=0.88,95%CI 0.80-0.96;
OR=1.20,95%CI 1.08-1.35, respectively] and ACA posi-
tive subgroups[OR=0.86,95%CI 0.77-0.97;OR=1.23, 95%
CI 1.07-1.42, respectively]. † Contributed equally
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O u rd a t ac o n f i r mt h ei n f l u e n c eo fTNFSF4 polymorph-
isms in SSc genetic susceptibility, especially with lcSSc
and ACA positive subsets of patients.
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